Ongoing clinical trials with ASOs targeting Bcl-2 (NCT04072458), Grb2 (NCT04196257), and androgen receptor (AR; NCT03300505) as well as future mRNA (Laikova et al., 2019) and non-coding RNA targets (Slack and Chinnaiyan, 2019) for the treatment of various solid tumors will in time tell of the efficacy of ASOs for cancer treatment. Here, AR is linked to cancer.